Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young Adults (AMEND)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03798574
Recruitment Status : Recruiting
First Posted : January 10, 2019
Last Update Posted : October 14, 2020
Sponsor:
Information provided by (Responsible Party):
Helen Marshall, University of Adelaide

Brief Summary:

Survivors of invasive meningococcal disease (IMD) experience a range of mild to severe sequelae that impact upon their quality of life. The majority of studies to date have focused on the impact of IMD on childhood and very little is known about the impact of the disease on adolescents and young people.

The aim of this study is to assess the physical, neurocognitive, economic and societal impact of IMD on adolescents and young adult Australian survivors.

Hypothesis:

  1. Adolescents and young adult survivors who are 2 to 10 years post IMD have significantly poorer outcomes including intellectual functioning and quality of life when compared to healthy controls.
  2. IMD imposes a significant financial burden upon individuals, families and society.
  3. Serogroup B disease is associated with an increased risk of sequelae when compared to non-B serogroup IMD.

Study design:

This a multi-centre, case-control mixed-methods study. Survivors of IMD (retrospective and prospective cases) and non-IMD healthy controls will be invited to participate in the study.

Retrospective IMD cases admitted in the previous 10 years will be identified through each of the participating hospitals (paediatric and adult hospitals). During the course of the study prospective recruitment of IMD cases will also occur at participating hospitals. Meningococcal foundations/groups will also be approached and asked to advertise and conduct a mail out to their members to inform them about the study.

Healthy controls will be prospectively recruited by "snowballing technique" whereby enrolled IMD cases will be asked to distribute a study information sheet to their healthy friends/acquaintances who are approximately the same age. Control participants may also be identified from databases at each participating site or through community advertising.

Enrolled cases will undergo a neurocognitive, psychological and physical examination 2 - 10 years post IMD admission. A subset of IMD cases will be invited to participate in a semi-structured interview. Controls will also undergo neurocognitive, psychological and physical examination.


Condition or disease
Meningococcal Infections Neisseria Meningitis Sepsis Neisseria Infection

Layout table for study information
Study Type : Observational
Estimated Enrollment : 64 participants
Observational Model: Case-Control
Time Perspective: Other
Official Title: The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young Adults
Actual Study Start Date : March 1, 2016
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2021


Group/Cohort
IMD Case
No intervention
Control
No intervention



Primary Outcome Measures :
  1. Difference in intellectual functioning between cases and controls [ Time Frame: Between 2 to 10 years post IMD admission ]
    Measured by the Full Scale intelligence quotient (IQ) score obtained from the Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV)

  2. Difference in quality of life between cases and controls [ Time Frame: Between 2 to 10 years post IMD admission ]
    Measured by the overall multi-attribute health utility score obtained from the Health Utilities Index Mark 3 (HUI3)-15Q self-report.


Secondary Outcome Measures :
  1. Difference in academic achievement between cases and controls. [ Time Frame: Between 2 to 10 years post IMD admission ]
    Measured by Wechsler Individual Achievement Test - Second Edition (WIAT-II)

  2. Difference in memory (verbal and visual) between cases and controls. [ Time Frame: Between 2 to 10 years post IMD admission ]
    Measured by Verbal Learning and Design Memory subtests from the Wide Range Assessment of Memory and Learning, Second Edition (WRAML2)

  3. Difference in executive functioning between cases and controls. [ Time Frame: Between 2 to 10 years post IMD admission ]
    Measured by Delis-Kaplan Executive Function System (D-KEFS)

  4. Difference in executive functioning between cases and controls assessed through BRIEF self-report questionnaire [ Time Frame: Between 2 to 10 years post IMD admission ]
    Assessed through BRIEF self-report questionnaire (parent and/or self-report)

  5. Difference in the frequency of psychiatric disorders between cases and controls. [ Time Frame: Between 2 to 10 years post IMD admission ]
    Assessed through Mini International Neuropsychiatric Interview (M.I.N.I 6.0)

  6. Difference in psychological functioning between cases and controls. [ Time Frame: Between 2 to 10 years post IMD admission ]
    Assessed through self report questionnaire Depression Anxiety Stress Scales (DASS) (self-report)

  7. Difference in behavioral ratings between cases and controls [ Time Frame: Between 2 to 10 years post IMD admission ]
    Measured by Conners Rating Scales (parent and/or self-report)

  8. Difference in health and disability functioning between cases and controls [ Time Frame: Between 2 to 10 years post IMD admission ]
    Measured by the International Classification of Functioning, Disability and Health (ICF) tool.

  9. Difference in hearing threshold levels between cases and controls [ Time Frame: Between 2 to 10 years post IMD admission ]
    Measured by pure tone audiometry.

  10. Difference in health status between cases and controls [ Time Frame: Between 2 to 10 years post IMD admission ]
    The EQ-5D-5L will be completed to measure participant's health status and to calculate quality adjusted life years (QALYS) lost.

  11. To estimate the lifetime costs associated with survival following IMD [ Time Frame: From time of admission up to time of follow up (2 to 10 years post IMD admission) ]
    IMD cases only: Lifetime dollar costs.

  12. Explore adolescents and young people's experience of their hospital presentation, admission, and recovery from IMD [ Time Frame: Between 2 to 10 years post IMD admission ]
    A subset of IMD cases will participate in a semi-structured interview.

  13. Carer's experience assessed through the Carer Experience Scale [ Time Frame: Between 2 to 10 years post IMD admission ]
    For those IMD cases with a disability, the primary caregiver and other family members living in the same household will be invited to complete the Carer Experience Scale.

  14. Carer's experience assessed through ICEpop CAPability questionnaires [ Time Frame: Between 2 to 10 years post IMD admission ]
    For those IMD cases with a disability, the primary caregiver and other family members living in the same household will be invited to complete ICEpop CAPability questionnaire.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   15 Years to 24 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Population sample from participating Australian hospitals in Adelaide, Melbourne, Perth, and Sydney.
Criteria

Inclusion Criteria:

  • Patients aged 15 to 24 years 11 months at time of IMD admission
  • Hospitalised IMD case from 1st January 2006 -with serogroup B or non-B IMD, confirmed by culture or polymerase chain reaction (PCR) in blood or CSF.
  • Healthy controls aged 17 to 34 years 11 months at the time of assessment.

Exclusion Criteria:

  • Individuals who are not fluent with the English language.
  • Control participants with a history of meningitis, encephalitis, or meningococcal disease, intellectual disability, intracranial pathology (eg. traumatic brain injury) that may impact on cognitive functioning, or significant vision and/or hearing loss that may impact on the validity or reliability of the neurocognitive assessment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03798574


Contacts
Layout table for location contacts
Contact: Helen Marshall 8161 8115 helen.marshall@adelaide.edu.au
Contact: Mark McMillan 0881618105 mark.mcmillan@adelaide.edu.au

Locations
Layout table for location information
Australia, New South Wales
The Children's Hospital at Westmead Not yet recruiting
Westmead, New South Wales, Australia, 2145
Contact: Belinda Barton    (02) 9845 0415      
Principal Investigator: Robert Booy         
Principal Investigator: Belinda Barton         
Australia, South Australia
Women's and Children's Hosptial Recruiting
Adelaide, South Australia, Australia, 5006
Contact: Helen Marshall    0881618115    helen.marshall@adelaide.edu.au   
Contact: Mark McMillan    0881618105    mark.mcmillan@adelaide.edu.au   
Principal Investigator: Helen Marshall         
Australia, Victoria
Monash Children's Hospital, Melbourne Recruiting
Clayton, Victoria, Australia, 3168
Contact: Margaret Angliss       Margaret.Angliss@monashhealth.org   
Principal Investigator: Jim Buttery         
Australia, Western Australia
Perth Children's Hospital Recruiting
Nedlands, Western Australia, Australia, 6009
Contact: Jane Jones       Jane.Jones@telethonkids.org.au   
Principal Investigator: Chris Blyth         
Sponsors and Collaborators
University of Adelaide
Investigators
Layout table for investigator information
Principal Investigator: Helen Marshall University of Adelaide
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Helen Marshall, Professor, University of Adelaide
ClinicalTrials.gov Identifier: NCT03798574    
Other Study ID Numbers: HREC/14/WCHN/024
First Posted: January 10, 2019    Key Record Dates
Last Update Posted: October 14, 2020
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Meningococcal Infections
Meningitis
Central Nervous System Diseases
Nervous System Diseases
Neisseriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections